Скачать с ютуб Highlights from the ASH 2022 Annual Meeting: A Canadian Perspective в хорошем качестве

Highlights from the ASH 2022 Annual Meeting: A Canadian Perspective

Four Canadian hematologists (Ali Amid, MD, Deborah Siegal, MD, MSc, FRCPC, Roona Sinha, MD, Leslie Skeith, MD, FRCPC, MHPE) share their highlights from the presentations at ASH 2022. This program was jointly presented by Thrombosis Canada and the AHCDC, with presentations on thrombosis and hemophilia. Presentations highlighted included: - Social Determinants of Health and PE Treatment and Mortality: The Nationwide Inpatient Sample - Early Dynamics of C-Reactive Protein Predict Risk of VTE in Patients with - --- Cancer Treated with Immune Checkpoint Inhibitors - A Prospective Study of Apixaban for Central Venous Catheter Associated - -- Upper Extremity Deep Vein Thrombosis in Cancer Patients: Catheter 3 - LMWH Versus Standard Pregnancy Care for Women with Recurrent - - - ----- - - Miscarriage and Inherited Thrombophilia (ALIFE2) - Engineered Biomaterials for Hemostasis - Gene Therapies to Enhance the Hemostatic Function of Platelets - ASH ISTH NHF WFH Guidelines on VWD: Impact on Patients, Policy, and Allied Health Professionals - What Have We Learned About the Patient's Experience with von Willebrand Disease? - Hemorrhagic and Thrombotic Adverse Events Associated with Emicizumab and Extended Half-Life FVIII Replacement Drugs in Patients with Hemophilia: - Data from the Eudravigilance Database - Pediatric Splanchnic Vein Thrombosis: Systematic Review and Meta-Analysis